NEWPORT INTERNATIONAL JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES (NIJSES)

Volume 7 Issue 2 Page 125-130, 2026

ONLINE ISSN:2992-5819 PRINT ISSN:2992-6149

Open Access

https://doi.org/10.59298/NIJSES/2026/72.125130

Role of Nanotechnology in Modulating Gut–Adipose Axis Inflammation in Obesity

Nakawungu Catherine

Department of Pharmaceutical Microbiology and Biotechnology Kampala International University Uganda

Email: catherine.nakawungu@studwc.kiu.ac.ug

ABSTRACT

Obesity, characterized by excessive fat accumulation and chronic low-grade inflammation, contributes significantly to metabolic disorders such as insulin resistance, type 2 diabetes, and cardiovascular diseases. The interplay between the gut microbiota and adipose tissue inflammation, known as the gut–adipose axis, is central to the pathogenesis of obesity-related complications. Dysbiosis, or an imbalance in the gut microbiota, triggers systemic inflammation that affects adipose tissue, promoting the development of insulin resistance and metabolic syndrome. Nanotechnology offers innovative approaches to modulate this gut–adipose axis by targeting the underlying inflammatory processes. Nanomaterials, including nanoparticles (NPs), nanostructured lipid carriers (NLCs), and nanocomposites, can deliver anti-inflammatory agents or probiotics to modulate gut microbiota composition, improve intestinal permeability, and directly reduce adipose tissue inflammation. These smart nanomaterials respond to the microenvironmental signals of inflammation, offering controlled and targeted delivery of therapeutic agents, thereby improving the effectiveness of treatment while minimizing side effects. This review discusses the role of nanotechnology in modulating the gut–adipose axis inflammation in obesity, the mechanisms of action, current therapeutic applications, and challenges associated with translating nanotechnologies into clinical practice. By harnessing nanotechnology, new strategies for managing obesity and its related metabolic disorders could emerge, offering personalized, effective treatments.

Keywords: Gut–adipose axis; Obesity; Inflammation; Nanotechnology; Nanoparticles

INTRODUCTION

Obesity is a global health crisis that affects millions of people worldwide and is associated with an increased risk of metabolic disorders such as insulin resistance, type 2 diabetes, and cardiovascular diseases[1–4]. Over the past few decades, research has increasingly focused on understanding the complex mechanisms behind obesity, and one of the most significant areas of exploration has been the role of inflammation in the pathogenesis of obesity-related complications. While inflammation in white adipose tissue (WAT) has been well-studied, recent evidence points to the gut microbiota as an important player in the inflammatory response associated with obesity[5–8]. The gut–adipose axis refers to the bidirectional communication between the gastrointestinal tract and adipose tissue, which plays a pivotal role in the development and progression of obesity and its associated metabolic disorders[3, 9–11].

Under normal conditions, the gut microbiota contributes to metabolic homeostasis by regulating nutrient absorption, modulating immune responses, and producing metabolites that influence adipose tissue function[10, 12, 13]. However, in obese individuals, the gut microbiota undergoes dysbiosis, characterized by a reduction in beneficial microbes and an increase in pro-inflammatory bacteria. This dysbiosis disrupts the gut barrier function, leading to increased intestinal permeability ("leaky gut"), which allows the translocation of bacterial products (e.g., lipopolysaccharides) into the bloodstream. These microbial-derived molecules trigger systemic inflammation and activate immune responses that ultimately promote the inflammatory processes in adipose

tissue[13]. Adipocytes, particularly in visceral fat, become infiltrated with immune cells such as macrophages, which secrete pro-inflammatory cytokines and contribute to insulin resistance.

The role of the gut microbiota and its impact on the gut–adipose axis presents a novel therapeutic target for modulating inflammation in obesity[14]. Recent advances in nanotechnology offer promising solutions to address these challenges[15]. Nanomaterials, including nanoparticles (NPs), nanostructured lipid carriers (NLCs), and nanocomposites, are being explored for their ability to deliver drugs, probiotics, and other therapeutic agents to the gut and adipose tissue with high precision. The ability to engineer these nanomaterials to respond to specific biochemical and environmental cues allows for controlled, targeted drug delivery, which could provide a more effective and personalized approach to managing obesity-related inflammation[15].

Nanotechnology has been employed to deliver a wide range of therapeutic agents aimed at restoring gut homeostasis, enhancing intestinal barrier integrity, and reducing the inflammatory burden in adipose tissue[16]. For example, probiotics, prebiotics, and anti-inflammatory agents can be encapsulated in nanomaterials that protect them from degradation in the gastrointestinal tract while facilitating targeted release at the site of action. Additionally, nanoparticles functionalized with targeting ligands have shown promise in selectively delivering drugs to inflamed adipose tissue or gut epithelial cells, thereby reducing systemic toxicity and improving therapeutic efficacy[16]. This review explores the role of nanotechnology in modulating the gut–adipose axis inflammation in obesity. It discusses the molecular mechanisms underlying the gut–adipose axis, how nanotechnology can address inflammation in both the gut and adipose tissue, and the potential therapeutic applications of nanomaterials. We will also examine current challenges and future perspectives regarding the clinical translation of nanotechnology in treating obesity and its related disorders.

2. The Gut–Adipose Axis and Inflammation in Obesity

The gut–adipose axis is a complex network of interactions between the gastrointestinal tract and adipose tissue, both of which play integral roles in regulating metabolic processes[17]. The gut microbiota, consisting of trillions of microbes, has emerged as a key mediator of the gut–adipose axis. The gut microbiota influences adipose tissue function through several mechanisms, including the production of short-chain fatty acids (SCFAs), bile acids, and other metabolites that regulate fat storage, energy metabolism, and immune responses[18, 19].

In obesity, gut microbiota dysbiosis leads to a disrupted balance of beneficial and pathogenic microbes. A reduction in the diversity of gut microbes, particularly an imbalance between Firmicutes and Bacteroidetes phyla, has been associated with increased adiposity and inflammation. Dysbiosis results in the increased production of pro-inflammatory metabolites, such as lipopolysaccharides (LPS), which contribute to gut barrier dysfunction[18]. Increased gut permeability allows microbial products like LPS to enter the bloodstream, triggering systemic inflammation and activating immune cells, including macrophages and T cells, which infiltrate adipose tissue and promote the secretion of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β. These cytokines disrupt insulin signaling in adipocytes and other insulin-sensitive tissues, contributing to insulin resistance and metabolic dysfunction[20, 21].

The chronic low-grade inflammation observed in both the gut and adipose tissue plays a crucial role in the pathogenesis of obesity and its associated comorbidities, including metabolic syndrome, non-alcoholic fatty liver disease, and type 2 diabetes[22, 23]. Given the importance of the gut–adipose axis in obesity-related inflammation, targeting the inflammation in both organs is a promising strategy for managing obesity and its complications.

Nanotechnology-based strategies provide a novel approach to modulating the gut–adipose axis by targeting the inflammatory processes that occur in both the gut and adipose tissue[6, 24, 25]. Nanomaterials can be designed to target gut epithelial cells, restore gut barrier integrity, and modulate the composition of the gut microbiota. Additionally, nanomaterials can be engineered to deliver anti-inflammatory drugs or other therapeutics directly to adipose tissue, thereby reducing systemic inflammation and improving insulin sensitivity.

3. Mechanisms of Nanotechnology in Modulating Gut–Adipose Axis Inflammation

Nanotechnology offers several mechanisms for targeting inflammation in the gut and adipose tissue through controlled drug release and modulation of the microbiota. One of the most significant advantages of nanomaterials is their ability to respond to the unique biochemical environment of inflamed tissues. Several strategies have been developed to utilize nanomaterials for modulating gut–adipose axis inflammation, including the following:

1. **Microbiota Modulation**: Nanomaterials such as probiotics and prebiotics encapsulated in nanoparticles have shown potential in modulating gut microbiota composition[26]. These nanomaterials protect the probiotics from harsh gastrointestinal conditions, such as low pH and digestive enzymes, ensuring their viability and release at the desired site in the gut. Furthermore, nanomaterials can facilitate the controlled release of prebiotics that promote the growth of beneficial microbes, thereby restoring microbial balance and preventing dysbiosis[26].
2. **Enhancing Intestinal Barrier Function**: In obesity, intestinal permeability is increased due to gut microbiota dysbiosis, leading to the translocation of bacterial endotoxins (e.g., LPS) into the bloodstream[26]. Nanoparticles designed to target intestinal epithelial cells can enhance the integrity of the gut barrier by promoting tight junction formation or inhibiting inflammatory pathways that

compromise the barrier. For instance, nanoparticles containing anti-inflammatory agents such as curcumin or resveratrol have been shown to reduce intestinal inflammation and improve gut permeability[27].

3. **Targeted Drug Delivery**: Nanomaterials functionalized with ligands that target specific receptors on inflamed adipocytes or gut epithelial cells allow for targeted delivery of anti-inflammatory drugs or insulin-sensitizing agents[28]. This targeted approach reduces the risk of off-target effects and systemic toxicity, improving therapeutic outcomes. Nanoparticles can also be engineered to release their payload in response to specific inflammatory signals, such as low pH or elevated oxidative stress, ensuring that the therapeutic agents are released only in inflamed tissues[28].
4. **Modulation of Immune Cells**: Nanoparticles can also be used to modulate immune cell function within adipose tissue and the gut. For example, nanoparticles can be designed to specifically target macrophages in adipose tissue, reprogramming them from the pro-inflammatory M1 phenotype to the anti-inflammatory M2 phenotype[29, 30]. This shift reduces the production of inflammatory cytokines and restores insulin sensitivity. Similarly, nanoparticles targeting gut-associated lymphoid tissue (GALT) can modulate systemic immune responses, preventing the activation of inflammatory pathways that contribute to obesity-related inflammation[31].

4. Nanotechnology Applications in Obesity-Related Chronic Inflammation

Nanotechnology-based approaches have shown promise in various preclinical studies targeting obesity-related inflammation in both the gut and adipose tissue. Some key applications include:

1. **Probiotic Delivery**: Probiotics encapsulated in nanoparticles offer a highly efficient method for delivering live microbes to the gut, where they can promote a healthy microbiome. Nanoparticles can protect probiotics from degradation and ensure their stable release at the site of action[26]. Recent studies have demonstrated that probiotic-loaded nanoparticles can restore gut microbiota diversity, reduce intestinal permeability, and lower levels of pro-inflammatory cytokines in adipose tissue, thereby improving insulin sensitivity and reducing adiposity[32].
2. **Anti-Inflammatory Drug Delivery**: Nanoparticles have been utilized to deliver anti-inflammatory drugs such as curcumin, resveratrol, and nonsteroidal anti-inflammatory drugs (NSAIDs) directly to the gut or adipose tissue. These drugs can target the root causes of inflammation, such as oxidative stress and cytokine release, and modulate the immune response[33, 34]. Studies have shown that anti-inflammatory nanoparticle formulations can reduce visceral fat mass, improve glucose metabolism, and enhance adipose tissue insulin sensitivity.
3. **Gene Therapy**: Nanotechnology also holds promise for gene-based therapies aimed at modulating gut–adipose axis inflammation. For example, nanoparticles can be used to deliver small interfering RNAs (siRNAs) or messenger RNAs (mRNAs) targeting inflammatory mediators or genes involved in adipocyte dysfunction[35]. Such gene therapies could potentially reprogram adipose tissue macrophages, reduce adipose tissue inflammation, and restore normal metabolic function.
4. **Nanoformulations for Insulin Sensitization**: Nanoparticles can also be used to deliver insulin-sensitizing agents, such as metformin or thiazolidinediones (TZDs), directly to adipose tissue[36]. These formulations help reduce systemic side effects and increase drug efficacy by targeting the adipose tissue microenvironment.

5. Challenges and Future Directions

Despite the promising potential of nanotechnology in modulating the gut–adipose axis, several challenges remain in translating these technologies to clinical practice. Some of the key issues include:

1. **Biocompatibility and Safety**: Nanomaterials, particularly those composed of inorganic components, can potentially accumulate in tissues and cause long-term toxicity[37]. Ensuring the biocompatibility of nanoparticles is crucial for their safe use in human patients. The long-term effects of repeated exposure to nanomaterials in the gastrointestinal tract and adipose tissue must be carefully evaluated.
2. **Targeting Efficiency**: One of the primary advantages of nanotechnology is the ability to target specific tissues[38]. However, the efficiency of targeting nanomaterials to the gut and adipose tissue remains a challenge. Strategies to enhance the targeting specificity, such as functionalizing nanoparticles with targeting ligands, need further optimization to improve therapeutic outcomes[38].
3. **Scalability and Manufacturing**: The production of nanoparticles in large quantities for clinical use remains a challenge[39]. Developing scalable manufacturing methods for high-quality nanoparticles with consistent properties is essential for the successful commercialization of these technologies.
4. **Regulatory Hurdles**: The use of nanotechnology in medicine faces stringent regulatory requirements[40]. Comprehensive studies on the safety, efficacy, and pharmacokinetics of nanomaterials are necessary to meet regulatory standards and ensure the approval of these therapies.

In the future, combining nanotechnology with other emerging therapies, such as microbiome-based interventions, could provide a more comprehensive approach to modulating the gut–adipose axis and treating obesity-related inflammation.

CONCLUSION

Nanotechnology offers a promising approach to modulating the gut–adipose axis in obesity by targeting inflammation in both the gut and adipose tissue. Through the use of nanoparticles and other nanomaterials, it is possible to deliver probiotics, anti-inflammatory agents, and other therapeutics with high precision, improving the efficacy of treatment while minimizing side effects. Although significant progress has been made in preclinical studies, challenges such as biocompatibility, targeting efficiency, and scalability remain. Addressing these issues will be crucial for the successful translation of nanotechnology into clinical practice. With further research and development, nanotechnology has the potential to revolutionize the treatment of obesity and its associated metabolic disorders, offering more effective, personalized therapeutic strategies.

REFERENCES

1. Alanazi, A., Craven, A., Spirou, S.V., Santos-Martinez, M.J., Medina, C., Gobbo, O.L.: Nanomedicine as a Promising Treatment Approach for Obesity. J. Nanotheranostics. 6, (2025). https://doi.org/10.3390/jnt6030021
2. Anand, S., Patel, T.N.: Integrating the metabolic and molecular circuits in diabetes, obesity and cancer: a comprehensive review. Discov. Oncol. 15, 779 (2024). https://doi.org/10.1007/s12672-024-01662-1
3. Anguita-Ruiz, A., Bustos-Aibar, M., Plaza-Díaz, J., Mendez-Gutierrez, A., Alcalá-Fdez, J., Aguilera, C.M., Ruiz-Ojeda, F.J.: Omics Approaches in Adipose Tissue and Skeletal Muscle Addressing the Role of Extracellular Matrix in Obesity and Metabolic Dysfunction. Int. J. Mol. Sci. 22, 2756 (2021). https://doi.org/10.3390/ijms22052756
4. Obeten, U.N., Udeozor, P.A., Agada, S.A., Bawa, I., Ogbu, C.O.: Cytokines as key players in obesity low grade inflammation and related complications. Obes. Med. 54, 100585 (2025). https://doi.org/10.1016/j.obmed.2025.100585
5. Umoru, G.U., Atangwho, I.J., David-Oku, E., Uti, D.E., Agwupuye, E.I., Obeten, U.N., Maitra, S., Subramaniyan, V., Wong, L.S., Aljarba, N.H., Kumarasamy, V.: Tetracarpidium conophorum nuts (African walnuts) up-regulated adiponectin and PPAR-γ expressions with reciprocal suppression of TNF-α gene in obesity. J. Cell. Mol. Med. 28, e70086 (2024). https://doi.org/10.1111/jcmm.70086
6. David-Oku, E., De Campos, O.C., Udeozor, P.A., Nfona, S.O., Lawal, B., Alum, E.U.: Modulation of Lipogenesis by Tetracarpidium conophorum Nuts via SREBP-1/ACCA-1/FASN Inhibition in Monosodium-Glutamate-Induced Obesity in Rats. Nat. Prod. Commun. 20, 1934578X251344035 (2025). https://doi.org/10.1177/1934578X251344035
7. Bartelt, A., Widenmaier, S.B., Schlein, C., Johann, K., Goncalves, R.L.S., Eguchi, K., Fischer, A.W., Parlakgül, G., Snyder, N.A., Nguyen, T.B., Bruns, O.T., Franke, D., Bawendi, M.G., Lynes, M.D., Leiria, L.O., Tseng, Y.-H., Inouye, K.E., Arruda, A.P., Hotamisligil, G.S.: Brown adipose tissue thermogenic adaptation requires Nrf1-mediated proteasomal activity. Nat. Med. 24, 292–303 (2018). https://doi.org/10.1038/nm.4481
8. Aloh, H., Obasi, D., Okoroh, P., Aniokete, U., & Emeruwa, A. (2025). Maternal Nutrition, Toxicants, and Epigenetic Programming of Obesity Across Generations. Diabetes Metabolic Syndrome and Obesity, Volume 18, 4873-4911. https://doi.org/10.2147/dmso.s579409
9. Gutiérrez, A., Miravet ,Daniel, and Domènech, A.: COVID-19 and urban public transport services: emerging challenges and research agenda. Cities Health. 5, S177–S180 (2021). https://doi.org/10.1080/23748834.2020.1804291
10. Jiang, Z., Mei, L., Li, Y., Guo, Y., Yang, B., Huang, Z., Li, Y.: Enzymatic Regulation of the Gut Microbiota: Mechanisms and Implications for Host Health. Biomolecules. 14, 1638 (2024). https://doi.org/10.3390/biom14121638
11. Li, R., Andreu-Sánchez, S., Kuipers, F., Fu, J.: Gut microbiome and bile acids in obesity-related diseases. Best Pract. Res. Clin. Endocrinol. Metab. 35, 101493 (2021). https://doi.org/10.1016/j.beem.2021.101493
12. Santhiravel, S., Bekhit, A.E.-D.A., Mendis, E., Jacobs, J.L., Dunshea, F.R., Rajapakse, N., Ponnampalam, E.N.: The Impact of Plant Phytochemicals on the Gut Microbiota of Humans for a Balanced Life. Int. J. Mol. Sci. 23, 8124 (2022). https://doi.org/10.3390/ijms23158124
13. Ugwu, O.P.-C., Edeh, F.O., Ainebyoona, C.: Unveiling the microbial orchestra: exploring the role of microbiota in cancer development and treatment. Discov. Oncol. 16, 646 (2025). https://doi.org/10.1007/s12672-025-02352-2
14. Ugwu, O.P.-C., Okon, M.B., Alum, E.U., Ugwu, C.N., Anyanwu, E.G., Mariam, B., Ogenyi, F.C., Eze, V.H.U., Anyanwu, C.N., Ezeonwumelu, J.O.C., Egba, S.I., Uti, D.E., Onohuean, H., Aja, P.M., Ugwu, M.N.: Unveiling the therapeutic potential of the gut microbiota–brain axis: Novel insights and clinical applications in neurological disorders. Medicine (Baltimore). 104, e43542 (2025). https://doi.org/10.1097/MD.0000000000043542
15. van Son, J., Koekkoek, L.L., La Fleur, S.E., Serlie, M.J., Nieuwdorp, M.: The Role of the Gut Microbiota in the Gut–Brain Axis in Obesity: Mechanisms and Future Implications. Int. J. Mol. Sci. 22, 2993 (2021). https://doi.org/10.3390/ijms22062993

16. Li, W., Zhan, M., Wen, Y., Chen, Y., Zhang, Z., Wang, S., Tian, D., Tian, S.: Recent Progress of Oral Functional Nanomaterials for Intestinal Microbiota Regulation. Pharmaceutics. 16, 921 (2024). https://doi.org/10.3390/pharmaceutics16070921
17. Borozan, S., Fernandez, C.J., Samee, A., Pappachan, J.M.: Gut–Adipose Tissue Axis and Metabolic Health. Curr. Issues Mol. Biol. 47, 424 (2025). https://doi.org/10.3390/cimb47060424
18. Zhong, Y., Lei, Y., Jiang, S., Chen, D., Wang, X., Wang, K., Liao, T., Liao, R., Gan, M., Niu, L., Zhao, Y., Chen, L., Zhou, X., Wang, Y., Zhu, L., Shen, L.: Advances in understanding the role of gut microbiota in fat deposition and lipid metabolism. J. Anim. Sci. Biotechnol. 16, 152 (2025). https://doi.org/10.1186/s40104-025-01284-9
19. Ugwu, O.P.-C., Alum, E.U., Okon, M.B., Obeagu, E.I.: Mechanisms of microbiota modulation: Implications for health, disease, and therapeutic interventions. Medicine (Baltimore). 103, e38088 (2024). https://doi.org/10.1097/MD.0000000000038088
20. Di Vincenzo, F., Del Gaudio, A., Petito, V., Lopetuso, L.R., Scaldaferri, F.: Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review. Intern. Emerg. Med. 19, 275–293 (2024). https://doi.org/10.1007/s11739-023-03374-w
21. Zhao, M., Chu, J., Feng, S., Guo, C., Xue, B., He, K., Li, L.: Immunological mechanisms of inflammatory diseases caused by gut microbiota dysbiosis: A review. Biomed. Pharmacother. 164, 114985 (2023). https://doi.org/10.1016/j.biopha.2023.114985
22. Alum, E.U.: Optimizing patient education for sustainable self-management in type 2 diabetes. Discov. Public Health. 22, 44 (2025). https://doi.org/10.1186/s12982-025-00445-5
23. Alum, E.U.: Circadian nutrition and obesity: timing as a nutritional strategy. J. Health Popul. Nutr. 44, 367 (2025). https://doi.org/10.1186/s41043-025-01102-y
24. Atangwho, I.J., Ugwu, O.P.-C., Egbung, G.E., Aja, P.M.: Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: advances in targeted delivery and precision therapeutics. J. Nanobiotechnology. 23, 336 (2025). https://doi.org/10.1186/s12951-025-03412-z
25. Ntaobeten, E., Obeten, U.N., Bawa, I., Agada, S.A., Ukam, C.I.-O., Egbung, G.E.: Antioxidants in cancer therapy mitigating lipid peroxidation without compromising treatment through nanotechnology. Discov. Nano. 20, 70 (2025). https://doi.org/10.1186/s11671-025-04248-0
26. Pandey, R.P., Dhiman, R., Chang, C.-M.: The potential of nanoencapsulated probiotics in the modulation of the gut microbiome. Nanomed. 20, 335–338. https://doi.org/10.1080/17435889.2025.2452152
27. Dimeji, I.Y., Ayodeji, A.S.: Pharmacological modulation of the gut microbiota and endotoxemia: A next-generation approach to treating metabolic syndrome. ASPET Discov. 1, 100010 (2025). https://doi.org/10.1016/j.aspetd.2025.100010
28. Ray, S., Moonshi, S.S., Ta, H.T.: "Therapies Through Gut:" Targeted Drug Delivery for Non-Gastrointestinal Diseases by Oral Administration. Adv. Healthc. Mater. 14, 2403162 (2025). https://doi.org/10.1002/adhm.202403162
29. Dacoba, T.G., Olivera, A., Torres, D., Crecente-Campo, J., Alonso, M.J.: Modulating the immune system through nanotechnology. Semin. Immunol. 34, 78–102 (2017). https://doi.org/10.1016/j.smim.2017.09.007
30. Zhang, H., Chen, H., Hu, X., Muhammad, W., Liu, C., Liu, W.: Inflammation-modulating polymeric nanoparticles: design strategies, mechanisms, and therapeutic applications. eBioMedicine. 118, 105837 (2025). https://doi.org/10.1016/j.ebiom.2025.105837
31. McCright, J., Ramirez, A., Amosu, M., Sinha, A., Bogseth, A., Maisel, K.: Targeting the Gut Mucosal Immune System Using Nanomaterials. Pharmaceutics. 13, 1755 (2021). https://doi.org/10.3390/pharmaceutics13111755
32. Kadam, O., Dalai, S., Chauhan, B., Guru, R.R., Mitra, S., Raytekar, N., Kumar, R.: Nanobiotechnology Unveils the Power of Probiotics: A Comprehensive Review on the Synergistic Role of Probiotics and Advanced Nanotechnology in Enhancing Geriatric Health. Cureus. 17, e80478. https://doi.org/10.7759/cureus.80478
33. Wang, H., Zhou, Y., Sun, Q., Zhou, C., Hu, S., Lenahan, C., Xu, W., Deng, Y., Li, G., Tao, S.: Update on Nanoparticle-Based Drug Delivery System for Anti-inflammatory Treatment. Front. Bioeng. Biotechnol. 9, 630352 (2021). https://doi.org/10.3389/fbioe.2021.630352
34. Recent advances in nanoparticle-based drug delivery systems for rheumatoid arthritis treatment. Nanoscale Adv. 4, 3479–3494 (2022). https://doi.org/10.1039/d2na00229a
35. Unnisa, A., Greig, N.H., Kamal, M.A.: Nanotechnology-based gene therapy as a credible tool in the treatment of Alzheimer's disease. Neural Regen. Res. 18, 2127–2133 (2023). https://doi.org/10.4103/1673-5374.369096
36. Andreadi, A., Lodeserto, P., Todaro, F., Meloni, M., Romano, M., Minasi, A., Bellia, A., Lauro, D.: Nanomedicine in the Treatment of Diabetes. Int. J. Mol. Sci. 25, (2024). https://doi.org/10.3390/ijms25137028

37. Elmowafy, E.M., Tiboni, M., Soliman, M.E.: Biocompatibility, biodegradation and biomedical applications of poly(lactic acid)/poly(lactic-co-glycolic acid) micro and nanoparticles. J. Pharm. Investig. 49, 347–380 (2019). https://doi.org/10.1007/s40005-019-00439-x
38. Srivastava, A., Ahmad, A., Siddiqui, S., Islam, A.: Innovations in targeted drug delivery: From nanotechnology to clinical applications. Nanotechnol. 9, 100336 (2026). https://doi.org/10.1016/j.nxnano.2025.100336
39. Herdiana, Y., Wathoni, N., Shamsuddin, S., Muchtaridi, M.: Scale-up polymeric-based nanoparticles drug delivery systems: Development and challenges. OpenNano. 7, 100048 (2022). https://doi.org/10.1016/j.onano.2022.100048
40. Nyazema, N.Z., Chanyandura, J.T., Kumar, P.O.: Nanomedicine and regulatory science: the challenges in Africa. Front. Biomater. Sci. 2, (2023). https://doi.org/10.3389/fbiom.2023.1184662

CITE AS: Nakawungu Catherine (2026). Role of Nanotechnology in Modulating Gut–Adipose Axis Inflammation in Obesity. NEWPORT INTERNATIONAL JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES, 7(2):125-130.
https://doi.org/10.59298/NIJSES/2026/72.125130